FDA Grants Breakthrough Status to Aidoc’s AI for Acute Conditions

Aidoc, a global leader in clinical artificial intelligence, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its multi-triage AI solution. 

The system can identify and flag a wide range of life-threatening and time-sensitive conditions from CT scans within a single clinical workflow. 

Built on CARE™, Aidoc’s clinical-grade foundation model with FDA-cleared solutions, and powered by the aiOS™ platform, it helps care teams prioritise high-risk patients quickly and consistently.

This marks the first FDA Breakthrough Device Designation for an AI system with such broad medical coverage. 

The programme supports technologies that advance the diagnosis or treatment of serious conditions and meet unmet clinical needs. 

The designation allows faster review of multiple disease indications under one submission, helping bring comprehensive AI tools into routine care while maintaining strong safety and accuracy standards.

Aidoc’s platform addresses rising patient volumes and workforce shortages by automatically triaging urgent cases and streamlining workflows to improve efficiency. 

CARE™ is trained on extensive clinical data, expanding safely across diseases and care settings. Integrated with aiOS™, it supports multiple AI applications. 

This milestone highlights Aidoc’s growing role in shaping the future of clinical AI, advancing faster and safer diagnosis across healthcare systems, and reinforcing its commitment to improving patient outcomes worldwide.